Sanofi-Aventis (SNY-N) Stock Predictions - Stockchase
WATCH LIST
18
Sanofi-Aventis (SNY-N)

ON STOCKCHASE SINCE May 2005

Pharma & Healthcare

Sanofi-Aventis

SNY-N

6 watching          
Join the Discussion

Sanofi-Aventis (SNY-N) SAVE Nov, 16, 2018, 3:09 pm

45.10 0.53 (1.18%)

About Sanofi-Aventis (SNY-N)

Sanofi S.A. is a French multinational pharmaceutical company headquartered in Gentilly, France, as of 2013 the world's fifth-largest by prescription sales. More at Wikipedia

What the experts are saying about SNY-N



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
Sanofi-Aventis(SNY-N) 

November 8, 2018

(A Top Pick Nov 22/17, Up 5%) They had come off a patent cliff. Now earnings are doing better. The whole US healthcare area is looking good. This one sells at a lower multiple than North American ones.
Pharma & Healthcare
0 0 0 0 0
0 comments
(A Top Pick Nov 22/17, Up 5%) They had come off a patent cliff. Now earnings are doing better. The whole US healthcare area is looking good. This one sells at a lower multiple than North American ones.
Pharma & Healthcare
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$44.980
Owned Owned
Yes

TOP PICK
Sanofi-Aventis(SNY-N) 

August 14, 2018

The best time to buy drug stocks is after they have faced a patent cliff. They have lots of cash but they have to find new drugs by research or buy buying. Sanofi has lost competitions to buy drugs because they won’t pay too much for them. The stock has been behaving better lately as some of the acquisitions have been doing well. He thinks this is a good time to buy. (Analysts’ price target is $48.25)

Pharma & Healthcare
0 0 0 0 0
0 comments

The best time to buy drug stocks is after they have faced a patent cliff. They have lots of cash but they have to find new drugs by research or buy buying. Sanofi has lost competitions to buy drugs because they won’t pay too much for them. The stock has been behaving better lately as some of the acquisitions have been doing well. He thinks this is a good time to buy. (Analysts’ price target is $48.25)

Pharma & Healthcare
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$41.300
Owned Owned
Yes

TOP PICK
Sanofi-Aventis(SNY-N) 

July 4, 2018

A French pharmaceutical company, who has been impacted by patent protection ending on some key products. They lost out on a couple of acquisitions, that the company felt was too expensive. He believes this is a long term hold that will pay off over time. Yield 4.4%. (Analysts’ price target is $46)

Pharma & Healthcare
0 0 0 0 0
0 comments

A French pharmaceutical company, who has been impacted by patent protection ending on some key products. They lost out on a couple of acquisitions, that the company felt was too expensive. He believes this is a long term hold that will pay off over time. Yield 4.4%. (Analysts’ price target is $46)

Pharma & Healthcare
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$40.670
Owned Owned
Yes

PAST TOP PICK
Sanofi-Aventis(SNY-N) 

April 19, 2018

(A Top Pick May 1/17, Down 12%)  He is being patient with it as they buy companies that are patient with new drugs. 

Pharma & Healthcare
0 0 0 0 0
0 comments

(A Top Pick May 1/17, Down 12%)  He is being patient with it as they buy companies that are patient with new drugs. 

Pharma & Healthcare
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$40.160
Owned Owned
Yes

COMMENT
Sanofi-Aventis(SNY-N) 

December 28, 2017

A direct competitor of Novo-Nordisk (NVO-N) in one part of their business. Their franchise in multiple sclerosis and vaccine business is their big powerhouse, but overall, revenues only grew by 2% in the quarter, and they've seen a drop off in their diabetes cardiovascular unit, which is where the growth is. He prefers Novo-Nordisk.

Pharma & Healthcare
0 0 0 0 0
0 comments

A direct competitor of Novo-Nordisk (NVO-N) in one part of their business. Their franchise in multiple sclerosis and vaccine business is their big powerhouse, but overall, revenues only grew by 2% in the quarter, and they've seen a drop off in their diabetes cardiovascular unit, which is where the growth is. He prefers Novo-Nordisk.

Pharma & Healthcare
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$43.060
Owned Owned
Unknown

TOP PICK
Sanofi-Aventis(SNY-N) 

November 22, 2017

An international health care company, mainly in rare diseases, MS, immunology and oncology. Has been growing both by acquisition and through drugs of its own. Earlier this year, they bought Boehringer Ingelheim’s consumer products division. The latest quarter was a little soft and the market has punished them. He doesn’t worry about quarter to quarter. They’ve developed some drugs with Regeneron. Their partnership is dissolving, but any drugs they’ve developed, will continue on. A good, long term investment. Dividend yield of 3.7%. (Analysts’ price target is $54.)

Pharma & Healthcare
0 0 0 0 0
0 comments

An international health care company, mainly in rare diseases, MS, immunology and oncology. Has been growing both by acquisition and through drugs of its own. Earlier this year, they bought Boehringer Ingelheim’s consumer products division. The latest quarter was a little soft and the market has punished them. He doesn’t worry about quarter to quarter. They’ve developed some drugs with Regeneron. Their partnership is dissolving, but any drugs they’ve developed, will continue on. A good, long term investment. Dividend yield of 3.7%. (Analysts’ price target is $54.)

Pharma & Healthcare
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$45.370
Owned Owned
Yes

PAST TOP PICK
Sanofi-Aventis(SNY-N) 

July 25, 2017

(Top Pick July 25/16, Up 18.67%)  They faced a patent cliff.  They invested in smaller companies.  He thinks the outlook is quite good.

Pharma & Healthcare
0 0 0 0 0
0 comments

(Top Pick July 25/16, Up 18.67%)  They faced a patent cliff.  They invested in smaller companies.  He thinks the outlook is quite good.

Pharma & Healthcare
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$48.070
Owned Owned
Yes

TOP PICK
Sanofi-Aventis(SNY-N) 

May 1, 2017

The ADR trades in New York.  He does well buying drug companies when out of favour.  They all face patent cliffs from time to time.  The made acquisitions of some promising new drugs.  They have an exemplary balance sheet.  People hated it because they were in France with an election pending.  (Analysts’ target:  $47.00).

Pharma & Healthcare
0 0 0 0 0
0 comments

The ADR trades in New York.  He does well buying drug companies when out of favour.  They all face patent cliffs from time to time.  The made acquisitions of some promising new drugs.  They have an exemplary balance sheet.  People hated it because they were in France with an election pending.  (Analysts’ target:  $47.00).

Pharma & Healthcare
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$47.260
Owned Owned
Yes

COMMENT
Sanofi-Aventis(SNY-N) 

December 28, 2016

Healthcare stocks are totally out of favour and look interesting. As this is in Europe, it is somewhat out of the grasp of what might happen in the US regulatory market.

Pharma & Healthcare
0 0 0 0 0
0 comments

Healthcare stocks are totally out of favour and look interesting. As this is in Europe, it is somewhat out of the grasp of what might happen in the US regulatory market.

Pharma & Healthcare
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$39.260
Owned Owned
Yes

TOP PICK
Sanofi-Aventis(SNY-N) 

July 25, 2016

French drug stock.  People hate French investments and people don’t like drug stocks.  They are facing a patent cliff.  The stock is down and this is historically the best place to buy drug stocks.  They will likely make acquisitions with their hoard of cash.

Pharma & Healthcare
0 0 0 0 0
0 comments

French drug stock.  People hate French investments and people don’t like drug stocks.  They are facing a patent cliff.  The stock is down and this is historically the best place to buy drug stocks.  They will likely make acquisitions with their hoard of cash.

Pharma & Healthcare
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$42.140
Owned Owned
Yes

DON'T BUY
Sanofi-Aventis(SNY-N) 

November 20, 2014

The big drop was related to the poor performance of the diabetes drug.  When the CEO gets let go after announcing poor earnings it is not a catalyst.  He wonders if they have a proper pipeline.  He suggests staying away from it although there is some definite value here.

Pharma & Healthcare
0 0 0 0 0
0 comments

The big drop was related to the poor performance of the diabetes drug.  When the CEO gets let go after announcing poor earnings it is not a catalyst.  He wonders if they have a proper pipeline.  He suggests staying away from it although there is some definite value here.

Pharma & Healthcare
0 0 0 0 0
0 comments
Darren Sissons

Vice Presi, Campbell Lee & Ross...

Price Price
$46.570
Owned Owned
No

WEAK BUY
Sanofi-Aventis(SNY-N) 

April 29, 2014

They missed their numbers by a little bit. They had a nice run, 3.7% yield, 14 times earnings.  This would be a great company to buy and sell off its parts.  It is not huge in any particular area.  It will benefit from the possibility of takeovers in the industry.  You get a good rate of return but you won’t get a huge upside.

Pharma & Healthcare
0 0 0 0 0
0 comments

They missed their numbers by a little bit. They had a nice run, 3.7% yield, 14 times earnings.  This would be a great company to buy and sell off its parts.  It is not huge in any particular area.  It will benefit from the possibility of takeovers in the industry.  You get a good rate of return but you won’t get a huge upside.

Pharma & Healthcare
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$53.330
Owned Owned
Unknown

COMMENT
Sanofi-Aventis(SNY-N) 

April 9, 2014

Has looked at this recently because they have some good drugs in their pipeline, but his preference right now in Europe is Shier (?) which he thinks is well-positioned.

Pharma & Healthcare
0 0 0 0 0
0 comments

Has looked at this recently because they have some good drugs in their pipeline, but his preference right now in Europe is Shier (?) which he thinks is well-positioned.

Pharma & Healthcare
0 0 0 0 0
0 comments
Mark Grammer

Managing D, Gluskin Sheff & Asso...

Price Price
$53.000
Owned Owned
No

BUY
Sanofi-Aventis(SNY-N) 

August 11, 2011

One of the largest and most popular drug companies in Europe. Has a strong product profile. French stocks, merely by their association, have been really hammered. Good stable business that will do well, irrespective of economic conditions. Good entry point.
Pharma & Healthcare
0 0 0 0 0
0 comments
One of the largest and most popular drug companies in Europe. Has a strong product profile. French stocks, merely by their association, have been really hammered. Good stable business that will do well, irrespective of economic conditions. Good entry point.
Pharma & Healthcare
0 0 0 0 0
0 comments
Charles Lannon

Director o, Toron Investment Man...

Price Price
$32.870
Owned Owned
No

DON'T BUY
Sanofi-Aventis(SNY-N) 

May 6, 2010

PE of 8%. Might be a value trap. Not a lot of growth prospects. Vaccine business does fairly well. Pharma business is struggling a little and not much in the pipe at this point. (See Top Picks.)
Pharma & Healthcare
0 0 0 0 0
0 comments
PE of 8%. Might be a value trap. Not a lot of growth prospects. Vaccine business does fairly well. Pharma business is struggling a little and not much in the pipe at this point. (See Top Picks.)
Pharma & Healthcare
0 0 0 0 0
0 comments
Karl Berger

Partner, Toron Investment Man...

Price Price
$31.770
Owned Owned
No

Showing 1 to 15 of 18 entries
Successfully Saved Company
Successfully Saved Company